CARTA, ANDREA
 Distribuzione geografica
Continente #
EU - Europa 3.113
NA - Nord America 422
AS - Asia 84
SA - Sud America 5
AF - Africa 1
OC - Oceania 1
Totale 3.626
Nazione #
IT - Italia 2.977
US - Stati Uniti d'America 416
IE - Irlanda 79
TW - Taiwan 35
DE - Germania 16
SE - Svezia 16
CN - Cina 15
GB - Regno Unito 10
CA - Canada 6
SG - Singapore 6
JP - Giappone 5
PH - Filippine 5
HK - Hong Kong 4
BR - Brasile 3
CH - Svizzera 3
FI - Finlandia 3
ID - Indonesia 3
IR - Iran 3
NL - Olanda 3
IL - Israele 2
PL - Polonia 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
BE - Belgio 1
CL - Cile 1
CO - Colombia 1
ES - Italia 1
IN - India 1
MU - Mauritius 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
RU - Federazione Russa 1
TR - Turchia 1
Totale 3.626
Città #
Cagliari 2.937
Menlo Park 234
Chandler 24
Fairfield 23
Taipei 17
New York 15
Nyköping 13
Houston 11
Storm Lake 11
Rome 10
Boardman 7
Redwood City 7
Wilmington 7
Ashburn 6
Cambridge 6
London 5
Seattle 5
Serramanna 5
Shanghai 5
Kaohsiung 4
Limerick 4
Singapore 4
Boston 3
Boydton 3
San Diego 3
Santa Maria 3
Tokyo 3
Woodbridge 3
Changsha 2
Dong Ket 2
Esslingen am Neckar 2
Helsinki 2
Jacksonville 2
Kraków 2
Langley 2
Lucan 2
Oristano 2
Ottawa 2
Tallahassee 2
Wuppertal 2
Ann Arbor 1
Audubon 1
Bolton 1
Borås 1
Boulder 1
Brussels 1
Calgary 1
Ciampino 1
College Station 1
Essen 1
Guangzhou 1
Henrico 1
Istanbul 1
Kashan 1
Kish 1
Kudus 1
Kyoto 1
Los Angeles 1
Mainz 1
Marrùbiu 1
Moscow 1
Mountain View 1
Nashua 1
Norwalk 1
Paderborn 1
Pisa 1
Port Louis 1
Porto Alegre 1
Pune 1
Quartu Sant'Elena 1
Renchen 1
Santiago 1
Shenzhen 1
Southwark 1
St Louis 1
Surabaya 1
Tel Aviv 1
Valenza 1
Wembley 1
Wernigerode 1
Whangarei 1
Zhengzhou 1
Totale 3.444
Nome #
Practical implementation of the Kelly criterion: optimal growth rate, number of trades, and rebalancing frequency for equity portfolios 1.432
Protocol for a pharmacogenetic study of antidepressants: characterization of drug-metabolizing profiles of cytochromes CYP2D6 and CYP2C19 in a Sardinian population of patients with major depressive disorder 662
On the Use of Markov Models in Pharmacoeconomics: Pros and Cons and Implications for Policy Makers 579
Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study 434
Cost–utility analysis of pharmacogenetic testing based on CYP2C19 or CYP2D6 in major depressive disorder: assessing the drivers of different cost-effectiveness levels from an Italian societal perspective 330
A scientometric analysis of the effect of COVID-19 on the spread of research outputs 129
A method to validate clustering partitions 90
Totale 3.656
Categoria #
all - tutte 5.456
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.456


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021801 0 0 0 106 177 47 48 30 21 35 202 135
2021/2022702 107 48 23 24 86 51 37 30 49 87 93 67
2022/20231.039 69 102 121 97 103 114 62 69 66 98 91 47
2023/20241.114 95 58 48 71 131 216 172 87 66 93 77 0
Totale 3.656